ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib


Thunnissen E., Lissenberg-Witte B., van den Heuvel M. M. , Monkhorst K., Skov B. G. , Sorensen J. B. , ...Daha Fazla

LUNG CANCER, cilt.138, ss.13-18, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 138
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.lungcan.2019.09.023
  • Dergi Adı: LUNG CANCER
  • Sayfa Sayıları: ss.13-18

Özet

Objective: Metastasized non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) rearrangement is usually sensitive to a range of ALK-tyrosine kinase inhibitors. ALK-positive NSCLC have been identified in pivotal phase III trials with fluorescence in situ hybridization (ALK FISH +). These tumors are also expressing the fusion product (ALK immunohistochemistry (IHC) +). However, discrepant cases occur, including ALK IHC + FISH-. The aim of this study was to collect ALK IHC + cases and compare within this group response to crizotinib treatment of ALK FISH + cases with ALK FISH- cases.